-
Mashup Score: 0Post-CDK4/6 Inhibitor Treatment: Guide to HR+/HER2- MBC - 13 day(s) ago
Guide to post-CDK4/6 inhibitor treatment for HR+/HER2- breast cancer. Learn resistance, therapies, and access with ASCO expertise.
Source: oncologytube.comCategories: General Medicine NewsTweet
-
Mashup Score: 8MATTERHORN Trial: Durvalumab Improves EFS in Gastric Cancer - 16 day(s) ago
Discover insights from the MATTERHORN trial, showcasing the impact of durvalumab combined with FLOT chemotherapy.
Source: oncologytube.comCategories: General Medicine NewsTweet-
🐐MATTERHORN Trial - Is It The G.O.A.T.? 💉Durvalumab Improves EFS in Gastric Cancer 📊67% vs. 59% at 24mo, HR 0.71. 🎬 VIDEO OVERVIEW Now Available! 📰In-Depth Info: https://t.co/oVG3uk1gPj #MATTERHORN #GastricCancer #Immunotherapy @Innov_Medicine @imedverse @_SEOM https://t.co/ziH7UD9M91
-
-
Mashup Score: 10New FDA Voucher Program: How It Impacts Oncology Drug Approvals - 16 day(s) ago
See how the FDA’s new voucher program impacts oncology drug approvals, focusing on speed and safety. Tailored for ASCO.org viewers.
Source: oncologytube.comCategories: General Medicine NewsTweet-
🚨 FDA Voucher Program Oncology Overview! 🌟The FDA’s new program slashes review times to 1-2 months, targeting innovative cures and unmet needs in oncology. 📊Impact on Cancer Research & Patient Access 🎬References: https://t.co/PDizlFtLhb @US_FDA @bjork5 @faiska_hsk_skt https://t.co/QiPA0FwmSz
-
-
Mashup Score: 10New FDA Voucher Program: How It Impacts Oncology Drug Approvals - 17 day(s) ago
See how the FDA’s new voucher program impacts oncology drug approvals, focusing on speed and safety. Tailored for ASCO.org viewers.
Source: oncologytube.comCategories: General Medicine NewsTweet-
🚨 FDA Voucher Program Oncology Overview! 🌟The FDA’s new program slashes review times to 1-2 months, targeting innovative cures and unmet needs in oncology. 📊Impact on Cancer Research & Patient Access 🎬References: https://t.co/PDizlFtLhb @US_FDA @bjork5 @faiska_hsk_skt https://t.co/QiPA0FwmSz
-
-
Mashup Score: 8HR+/HER2- MBC 2L Outcomes: Top 10 ASCO 2025 Breakthroughs - 18 day(s) ago
Explore HR+/HER2- metastatic breast cancer 2L outcomes with crucial insights from ASCO 2025 on median progression-free survival.
Source: oncologytube.comCategories: General Medicine NewsTweet-
🚨 TOP 10 ASCO 2025 HR+ HER2- MBC 2L Outcomes! 📊Ranked by mPFS 🎬Article: https://t.co/dGKOyxOmm7 🔟EMBER-3 trial - Fulvestrant/AI (ESR1m) 9⃣Fulvestrant Monotherapy (prior CDK4/6i) 8⃣Fulvestrant Monotherapy (no prior CDK4/6i) 7⃣EMBER-3 trial - Imlunestrant (ESR1m) https://t.co/PTePMEsWZy
-
-
Mashup Score: 16Bispecific Antibodies Cancer Therapy: 2025 Advances - 19 day(s) ago
Discover BsAb oncology & 2025 clinical trials. Explore bispecific antibodies cancer therapy on OncologyTube.com. Watch now!
Source: oncologytube.comCategories: General Medicine NewsTweet-
🚀Bispecific Antibodies Cancer Therapy 2025 📺Video Overview📺 📊Blinatumomab (69% MRD negativity in ALL), 🩸Elranatamab (60% myeloma response) 🫁Tarlatamab (25% SCLC). 📰 Article With References: https://t.co/CqGX4K3wdk #BsAb #CancerTherapy #Oncology2025 @DrSamuelBHume https://t.co/HqUFmJ8R5B
-
-
Mashup Score: 7China Leads Oncology Trials with 39% Share | OncologyTube - 20 day(s) ago
Explore how China oncology trials are revolutionizing cancer research with a remarkable increase in clinical trials.
Source: oncologytube.comCategories: General Medicine NewsTweet-
🇨🇳China NOW LEADS ONCOLOGY trials [VIDEO] 📺 🔥39% of ALL Trials in 2024! 📈25 new launches in 2023🪜132 in five years! 📊193 NAS over 20 yrs FULL Scoop Here: https://t.co/60bbzhlFxP @IQVIA_global #Oncology #CancerResearch #ASCO25 https://t.co/JQwKvH122z @cremieuxrecueil https://t.co/qtlCza2n2t
-
-
Mashup Score: 23HCC Treatment Selection: 2025 ASCO Video Guide - 22 day(s) ago
Explore HCC treatment selection with guidelines from ASCO 2025 to improve patient outcomes and management of hepatocellular carcinoma.
Source: oncologytube.comCategories: General Medicine NewsTweet-
🦮 Pts selection pts HCC Video Guide @ASCO 2025 🔬 92% vs 84% local control (2024 JCO RCT)! 🌞SBRT outshines RFA for HCC <3cm leads multifocal HCC, SIRT 🤼Debated (SARAH: 8.0 vs 9.9 mo) 🔍Explore & ASCO 2025 insights! 📰Article With References: https://t.co/cbzQgCjghK https://t.co/9HOsYhbILk
-
-
Mashup Score: 23
FDA approves taletrectinib for ROS1-positive NSCLC on June 11, 2025. Learn about trial results, dosage, and side effects in this easy guide.
Source: oncologytube.comCategories: General Medicine NewsTweet-
📺BREAKING VIDEO Overview: 🚨FDA Approves TALETRECTINIB 🫁NSCLC ROS1+ 🎉 TRUST-I Trial: 90% ORR 📊72% DOR ≥12mo naive!⏲️ 📰 Article With References: https://t.co/AxvpKDWO39 #CancerResearch #LungCancer #ASCO25 @imedverse @OncoAlert @GlopesMd @NarjustFlorezMD @CParkMD https://t.co/IimyrFeJEL
-
-
Mashup Score: 55ASCO 2025: Cancer Research on Lymphopenia & Immunity - 24 day(s) ago
Explore ASCO 2025 cancer research on treatment-induced lymphopenia and immune health. Insights for oncologists from Ohio State and Dana-Farber.
Source: oncologytube.comCategories: General Medicine NewsTweet-
🚨 48% ↑ mortality risk per 📉10% ALC drop in NSCLC pts (HR 1.48)! 👏93% cystectomy avoidance 🥼Dr. Pat Soon-Shiong @DrPatSoonShiong 🤔Easy To Understand Patient Explanation Included! 📰 Article With References: https://t.co/QKZCojcNt5 #ASCO25 #Oncology #Immunotherapy https://t.co/UUOuZcLIvX
-
🚨Post-CDK4/6 Guide to HR+/HER2- MBC 🔬@ASCO 2025 insights @jimmitti_teysiret al. 📸New VIDEO: PFS up to 13.2m with trastuzumab deruxtecan (DESTINY-Breast04) 📈Elacestrant Boosts PFS to 3.8m in ESR1+ (EMERALD) 📰Article with References: https://t.co/EvuakDPAin YouTube: https://t.co/S0dOFRE12M